The pharmacological chaperone 1-deoxygalactonojirimycin increases α-galactosidase A levels in Fabry patient cell lines

Author： Benjamin E. Flanagan J. Schilling A. Chang H. Agarwal L. Katz E. Wu X. Pine C. Wustman B. Desnick R. Lockhart D. Valenzano K.

Publisher： Springer Publishing Company

ISSN： 0141-8955

Source： Journal of Inherited Metabolic Disease, Vol.32, Iss.3, 2009-06, pp. : 424-440

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The ratio of α-galactosidase to β-glucuronidase activities in dried blood for the identification of female Fabry disease patients

By Lukacs Z. Keil A. Kohlschütter A. Beck M. Mengel E.

Journal of Inherited Metabolic Disease, Vol. 28, Iss. 5, 2005-09 ,pp. : 803-805

Springer Publishing Company

Access to resources Recommend Favorite

β-Galactosidase deficiency: An approach to chaperone therapy

By Suzuki Yoshiyuki

Journal of Inherited Metabolic Disease, Vol. 29, Iss. 2-3, 2006-04 ,pp. : 471-476

Springer Publishing Company

Access to resources Recommend Favorite

Fabry disease in a patient with Turner syndrome

By Brouns R. Eyskens F. Boeck K. Ceuterick-de Groote C. Broeck M. Broeckhoven C. Deyn P.

Journal of Inherited Metabolic Disease, Vol. 32, Iss. 1, 2009-12 ,pp. : 45-48

Springer Publishing Company

Access to resources Recommend Favorite

The Dutch Fabry cohort: Diversity of clinical manifestations and Gb₃ levels

By Vedder A. Linthorst G. Breemen M. Groener J. Bemelman F. Strijland A. Mannens M. Aerts J. Hollak C.

Journal of Inherited Metabolic Disease, Vol. 30, Iss. 1, 2007-02 ,pp. : 68-78

Springer Publishing Company

Access to resources Recommend Favorite

Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease

By Marchesan D.

Journal of Inherited Metabolic Disease, Vol. 35, Iss. 6, 2012-11 ,pp. : 1107-1117

Springer Publishing Company

Access to resources Recommend Favorite